Given its ability to modulate inflammation, promote osteogenesis, and counter stromal support of tumor cells, BMP6 may be particularly relevant for MM patients with active bone disease and persistent stromal dysregulation, despite remission of tumor burden. This evidence concerns the gene BMP6 and Miyoshi myopathy.